Recaticimab Injection Application Scope

Indication: Treatment of primary hypercholesterolemia and mixed dyslipidemia in adults, including patients with heterozygous familial hypercholesterolemia (HeFH) or non-familial hypercholesterolemia, particularly for those not achieving LDL-C targets with statins or statin-intolerant.

Recaticimab Injection Characteristics

Ingredients: Recaticimab (monoclonal antibody targeting PCSK9).
Properties: Fully human monoclonal antibody; inhibits PCSK9 → lowers LDL-C by increasing LDL receptor recycling.
Packaging Specification: 150 mg/mL × 1 syringe/box
Storage: Store at 2–8 °C; do not freeze. Protect from light.
Expiry Date: As printed on packaging.
Executive Standard: Per registered product quality standard.
Approval Number: As printed on label.
Date of Revision: As printed on label/package insert.
Manufacturer: Innovative Biologics Co., Ltd.

Guidelines for the Use of Aixinan

Dosage and Administration:
- Recommended Dose: Typically 150 mg every 4–12 weeks, adjust based on LDL-C response.
- Administration: Subcutaneous injection; rotate injection sites; do not shake the syringe.
- Missed Dose: Administer as soon as possible and resume scheduled interval. Do not double the next dose.
Adverse Reactions:
- Common Adverse Reactions: Injection site reactions (redness, swelling, pain), nasopharyngitis, flu-like symptoms, headache, fatigue.
- Serious Adverse Reactions: Allergic reactions, hypersensitivity, rare cases of severe injection site reactions, transient liver enzyme elevations.
Contraindications:
- Hypersensitivity to recaticimab or excipients.
- Pregnancy only if clearly needed.
Precautions:
- Monitor LDL-C levels regularly.
- Use caution in patients with active infection or immune disorders.
- Inform patients about possible injection site reactions.
- Contraception advised during treatment.

Recaticimab Injection Interactions

May interact with other lipid-lowering therapies; monitor for additive LDL-C lowering.
No major CYP-mediated interactions expected.
Avoid co-administration with other PCSK9 inhibitors.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.